Ding 1997.

Methods	participants could not be taking any lipid‐lowering drugs and had to adhere to a low‐cholesterol diet for at least 6 weeks 12‐week randomised double‐blind placebo‐controlled trial
Participants	46 type 2 diabetic patients stable diabetes control Placebo baseline TC : 6.2 mmol/L (240 mg/dL) Placebo baseline LDL‐C : 4.3 mmol/L (166 mg/dL) Placebo baseline HDL‐C : 1.2 mmol/L (46 mg/dL) Placebo baseline triglycerides: 1.6 mmol/L (142 mg/dL) Fluvastatin 20 mg/day baseline TC : 6.3 mmol/L (244 mg/dL) Fluvastatin 20 mg/day baseline LDL‐C : 4.5 mmol/L (174 mg/dL) Fluvastatin 20 mg/day baseline HDL‐C : 1.1 mmol/L (42.5 mg/dL) Fluvastatin 20 mg/day baseline triglycerides: 1.5 mmol/L (132 mg/dL)
Interventions	Placebo 0‐6 weeks Placebo 6‐12 weeks Fluvastatin 20 mg/day 0‐6 weeks Fluvastatin 40 mg/day 6‐12 weeks
Outcomes	per cent change from baseline at 6 weeks of serum TC, LDL‐C, HDL‐C, triglycerides and WDAEs
Source of Funding	unknown
Notes	Placebo 6‐12 weeks Fluvastatin 40 mg/day 6‐12 weeks groups were not analysed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random sequence generation was not reported
Allocation concealment (selection bias)	Unclear risk	Method of allocation concealment was not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind Lipid parameter measurements unlikely influenced by lack of proper blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	Low risk	no patient discontinued medication because of adverse effects
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	13% participants were not included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding was not reported